1-9 of 9
Gregory J. Riely
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

Rona Yaeger, Riccardo Mezzadra, Jenna Sinopoli, Yu Bian, Michelangelo Marasco, Esther Kaplun, Yijun Gao, HuiYong Zhao, Arnaud Da Cruz Paula, Yingjie Zhu, Almudena Chaves Perez, Kalyani Chadalavada, Edison Tse, Sudhir Chowdhry, Sydney Bowker, Qing Chang, Besnik Qeriqi, Britta Weigelt, Gouri J. Nanjangud, Michael F. Berger, Hirak Der-Torossian, Kenna Anderes, Nicholas D. Socci, Jinru Shia, Gregory J. Riely, Yonina R. Murciano-Goroff, Bob T. Li, James G. Christensen, Jorge S. Reis-Filho, David B. Solit, Elisa de Stanchina, Scott W. Lowe, Neal Rosen, Sandra Misale
Journal: Cancer Discovery
Cancer Discov (2023) 13 (1): 41–55.
https://doi.org/10.1158/2159-8290.CD-22-0405
Published: 09 January 2023
View article titled, Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer
Open the PDF for Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Smarca4 Inactivation Promotes Lineage-Specific Transformation and Early Metastatic Features in the Lung

Carla P. Concepcion, Sai Ma, Lindsay M. LaFave, Arjun Bhutkar, Manyuan Liu, Lydia P. DeAngelo, Jonathan Y. Kim, Isabella Del Priore, Adam J. Schoenfeld, Manon Miller, Vinay K. Kartha, Peter M.K. Westcott, Francisco J. Sánchez-Rivera, Kevin Meli, Manav Gupta, Roderick T. Bronson, Gregory J. Riely, Natasha Rekhtman, Charles M. Rudin, Carla F. Kim, Aviv Regev, Jason D. Buenrostro, Tyler Jacks
Journal: Cancer Discovery
Cancer Discov (2022) 12 (2): 562–585.
https://doi.org/10.1158/2159-8290.CD-21-0248
Published: 09 February 2022
View article titled, <em>Smarca4</em> Inactivation Promotes Lineage-Specific Transformation and Early Metastatic Features in the Lung
Open the PDF for <em>Smarca4</em> Inactivation Promotes Lineage-Specific Transformation and Early Metastatic Features in the Lung in another window
Includes: Supplementary data
Journal Articles

Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial

Gregory J. Riely, Joel W. Neal, D. Ross Camidge, Alexander I. Spira, Zofia Piotrowska, Daniel B. Costa, Anne S. Tsao, Jyoti D. Patel, Shirish M. Gadgeel, Lyudmila Bazhenova, Viola W. Zhu, Howard L. West, Tarek Mekhail, Ryan D. Gentzler, Danny Nguyen, Sylvie Vincent, Steven Zhang, Jianchang Lin, Veronica Bunn, Shu Jin, Shuanglian Li, Pasi A. Jänne
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2021) 11 (7): 1688–1699.
https://doi.org/10.1158/2159-8290.CD-20-1598
Published: 01 July 2021
View article titled, Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with <em>EGFR</em> Exon 20 Insertion Mutations from a Phase I/II Trial
Open the PDF for Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with <em>EGFR</em> Exon 20 Insertion Mutations from a Phase I/II Trial in another window
Includes: Supplementary data
Journal Articles

Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade

Kathryn C. Arbour, Anh Tuan Luu, Jia Luo, Hira Rizvi, Andrew J. Plodkowski, Mustafa Sakhi, Kevin B. Huang, Subba R. Digumarthy, Michelle S. Ginsberg, Jeffrey Girshman, Mark G. Kris, Gregory J. Riely, Adam Yala, Justin F. Gainor, Regina Barzilay, Matthew D. Hellmann
Journal: Cancer Discovery
Cancer Discov (2021) 11 (1): 59–67.
https://doi.org/10.1158/2159-8290.CD-20-0419
Published: 06 January 2021
View article titled, Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade
Open the PDF for Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade in another window
Includes: Supplementary data
Journal Articles

Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers

Vivek Subbiah, Igor Puzanov, Jean-Yves Blay, Ian Chau, A. Craig Lockhart, Noopur S. Raje, Juergen Wolf, José Baselga, Funda Meric-Bernstam, Jason Roszik, Eli L. Diamond, Gregory J. Riely, Eric J. Sherman, Todd Riehl, Bethany Pitcher, David M. Hyman
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2020) 10 (5): 657–663.
https://doi.org/10.1158/2159-8290.CD-19-1265
Published: 01 May 2020
View article titled, Pan-Cancer Efficacy of Vemurafenib in <em>BRAF</em><sup>V600</sup>-Mutant Non-Melanoma Cancers
Open the PDF for Pan-Cancer Efficacy of Vemurafenib in <em>BRAF</em><sup>V600</sup>-Mutant Non-Melanoma Cancers in another window
Includes: Supplementary data
Journal Articles

Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers

Alexander Drilon, Romel Somwar, Biju P. Mangatt, Henrik Edgren, Patrice Desmeules, Anja Ruusulehto, Roger S. Smith, Lukas Delasos, Morana Vojnic, Andrew J. Plodkowski, Joshua Sabari, Kenneth Ng, Joseph Montecalvo, Jason Chang, Huichun Tai, William W. Lockwood, Victor Martinez, Gregory J. Riely, Charles M. Rudin, Mark G. Kris, Maria E. Arcila, Christopher Matheny, Ryma Benayed, Natasha Rekhtman, Marc Ladanyi, Gopinath Ganji
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2018) 8 (6): 686–695.
https://doi.org/10.1158/2159-8290.CD-17-1004
Published: 31 May 2018
View article titled, Response to ERBB3-Directed Targeted Therapy in <em>NRG1</em>-Rearranged Cancers
Open the PDF for Response to ERBB3-Directed Targeted Therapy in <em>NRG1</em>-Rearranged Cancers in another window
Includes: Supplementary data
Journal Articles

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

Emmet J. Jordan, Hyunjae R. Kim, Maria E. Arcila, David Barron, Debyani Chakravarty, JianJiong Gao, Matthew T. Chang, Andy Ni, Ritika Kundra, Philip Jonsson, Gowtham Jayakumaran, Sizhi Paul Gao, Hannah C. Johnsen, Aphrothiti J. Hanrahan, Ahmet Zehir, Natasha Rekhtman, Michelle S. Ginsberg, Bob T. Li, Helena A. Yu, Paul K. Paik, Alexander Drilon, Matthew D. Hellmann, Dalicia N. Reales, Ryma Benayed, Valerie W. Rusch, Mark G. Kris, Jamie E. Chaft, José Baselga, Barry S. Taylor, Nikolaus Schultz, Charles M. Rudin, David M. Hyman, Michael F. Berger, David B. Solit, Marc Ladanyi, Gregory J. Riely
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2017) 7 (6): 596–609.
https://doi.org/10.1158/2159-8290.CD-16-1337
Published: 01 June 2017
View article titled, Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
Open the PDF for Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies in another window
Includes: Supplementary data
Journal Articles

Targeting ALK: Precision Medicine Takes on Drug Resistance

Jessica J. Lin, Gregory J. Riely, Alice T. Shaw
Journal: Cancer Discovery
Cancer Discov (2017) 7 (2): 137–155.
https://doi.org/10.1158/2159-8290.CD-16-1123
Published: 05 February 2017
View article titled, Targeting ALK: Precision Medicine Takes on Drug Resistance
Open the PDF for Targeting ALK: Precision Medicine Takes on Drug Resistance in another window
Journal Articles

Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor–Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations

Yelena Y. Janjigian, Egbert F. Smit, Harry J.M. Groen, Leora Horn, Scott Gettinger, D. Ross Camidge, Gregory J. Riely, Bushi Wang, Yali Fu, Vikram K. Chand, Vincent A. Miller, William Pao
Journal: Cancer Discovery
Cancer Discov (2014) 4 (9): 1036–1045.
https://doi.org/10.1158/2159-8290.CD-14-0326
Published: 01 September 2014
View article titled, Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor–Resistant <em>EGFR</em>-Mutant Lung Cancer with and without T790M Mutations
Open the PDF for Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor–Resistant <em>EGFR</em>-Mutant Lung Cancer with and without T790M Mutations in another window
Includes: Supplementary data